Financial Highlights - Total revenue for Q3 2025 was reported at $226,000, marking a 135% increase from $96,000 in Q3 2024 [9] - For the nine months ended September 30, 2025, total revenue reached $581,000, up 114% from $271,000 in the same period of 2024 [9] - GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $4,120,000 in Q3 2024 [9] - GAAP net loss for the nine months ended September 30, 2025, was $11,405,000, compared to $11,015,000 for the same period in 2024 [9] Commercial Highlights - Sales activities for the LockeT device outside the U.S. are increasing, with CE Mark approval generating interest in countries such as Germany, France, Italy, Spain, Portugal, the UK, and South Africa [2] - In October, five accounts in South Africa placed reorders for LockeT [2] - VIVO product line is gaining traction internationally, with the first purchase order from France received in October [2] Clinical Studies and Publications - Clinical studies and publications remain a priority, with an interview in EP Lab Digest highlighting the economic benefits of the LockeT device for venous closure after electrophysiology procedures [3] Company Outlook - The CEO of Catheter Precision expressed confidence in a pivotal growth period ahead, supported by a well-established pipeline and the completion of two VIVO clinical studies in 2025 [4] - The company anticipates a major expansion of its approved product lines across U.S. and international markets [4] - VIVO is positioned as a transformative approach to treating ventricular arrhythmias, potentially capturing a significant share of an underserved market [4]
Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations